| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We performed a basic research for the development of a novel oncolytic herpes simplex virus type 1 (HSV-1) targeting glioma initiating cells (GICs). Using a third generation oncolytic HSV-1, G47Δ, as the backbone, we constructed a novel oncolytic HSV-1, termed T-BMP4, by incorporating the human bone morphogenetic proteins 4 (BMP4) gene into the viral genome. T-BMP4 exhibited a potent efficacy in vitro for several GIC lines established from clinical glioma specimens. In mice intracranial GIC-tumor model, intratumoral injections with T-BMP4 significantly prolonged the survival compared with mock treatment. Further, T-BMP4 was significantly more efficacious than the control virus T-01. These results suggest that oncolytic HSV-1 armed with BMP4 exhibits enhanced therapeutic efficacy especially for GIC rich tumors, and may serve as a practical tool for the eradication of malignant glioma with high recurrence rate.
|
